Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Adma Biologics (ADMA) Receivables - Net (2016 - 2025)

Adma Biologics (ADMA) has disclosed Receivables - Net for 13 consecutive years, with $158.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Net rose 216.86% year-over-year to $158.4 million, compared with a TTM value of $158.4 million through Dec 2025, up 216.86%, and an annual FY2025 reading of $158.4 million, up 216.86% over the prior year.
  • Receivables - Net was $158.4 million for Q4 2025 at Adma Biologics, up from $137.7 million in the prior quarter.
  • Across five years, Receivables - Net topped out at $158.4 million in Q4 2025 and bottomed at $15.4 million in Q1 2021.
  • Average Receivables - Net over 5 years is $48.8 million, with a median of $29.3 million recorded in 2021.
  • The sharpest move saw Receivables - Net tumbled 45.74% in 2022, then soared 264.38% in 2025.
  • Year by year, Receivables - Net stood at $28.6 million in 2021, then crashed by 45.74% to $15.5 million in 2022, then skyrocketed by 76.85% to $27.4 million in 2023, then surged by 82.34% to $50.0 million in 2024, then surged by 216.86% to $158.4 million in 2025.
  • Business Quant data shows Receivables - Net for ADMA at $158.4 million in Q4 2025, $137.7 million in Q3 2025, and $109.7 million in Q2 2025.